Skip to content

A multicenter, randomized controlled clinical study on the therapeutic effect of edible sweet potato starch rich in amylose in patients with gastrointestinal bleeding

A multicenter, randomized controlled clinical study on the therapeutic effect of edible sweet potato starch rich in amylose in patients with gastrointestinal bleeding

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123909
Enrollment
Unknown
Registered
2026-04-30
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Bleeding

Interventions

Experimental Group:Edible sweet potato starch rich in amylose can stop bleeding
Control group:Thrombin powder stops bleeding

Sponsors

The Second Affiliated Hospital of the Army Medical University of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 75, gender not limited; 2.Early gastric cancer and precancerous lesions or other benign lesions of the digestive tract that require endoscopic submucosal dissection (ESD); 3.Patients who voluntarily accept and abide by this plan, receive timely re-examination and follow-up, and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Complicated gastrointestinal varices or hemangioma; 3. Severe anemia and coagulation disorders (Hb 2; PT(prothrombin time) was 10 seconds longer than the standard value; 4. Patients with definite preoperative diagnosis of hypertension, that is, systolic blood pressure >140mmHg or/and diastolic blood pressure >90mmHg; 5. Participants enrolled in other clinical trials 3 months before surgery or during the trial; 6. Unable to tolerate endoscopic submucosal dissection due to poor cardiopulmonary function;

Design outcomes

Primary

MeasureTime frame
The success rate of hemostasis for ESD bleeding;

Secondary

MeasureTime frame
The rate of adverse reactions in patients;Endoscope pipeline failure;The incidence of delayed bleeding after ESD;

Countries

China

Contacts

Public ContactYang Shiming

The Second Affiliated Hospital of the Army Medical University of the People's Liberation Army of China

13228686589@163.com+86 23 68755604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026